15 16 Background: Monocytes and macrophages are central to atherosclerosis, but how they 17 mark progression of human coronary artery disease (CAD) is unclear. We tested 18 whether patients' monocyte subtypes paired with their derived macrophage profiles 19 correlate with extent of CAD. 20 21 Methods: Peripheral blood was collected from 30 patients undergoing cardiac 22 catheterization, and patients were categorized as having no significant CAD, single 23 vessel disease, or multivessel disease according to the number of affected coronary 24 arteries. Mononuclear cells were measured for monocyte markers CD14 and CD16 by 25 flow cytometry, and separate monocytes were cultured into macrophages over 7 days 26 and measured for polarization markers CD86 and CD206. 27 28 Results: At baseline, patients with greater CAD burden were older with higher rates of 29 statin use, whereas all other characteristics were similar across the spectrum of 30 coronary disease. Non-classical (CD14 lo CD16 hi ) and all CD16 + monocytes were 31 elevated in patients with single vessel and multivessel disease compared to those 32 without significant CAD (8.6% and 10.5% vs. 2.8%, p < 0.05), whereas regulatory M2 33 macrophages (CD206 + ) were decreased in patients with single vessel and multivessel 34 disease (0.34% and 0.34% vs. 1.4%, p < 0.05). An inverse relationship between paired 35
INTRODUCTION

MATERIALS AND METHODS
Subjects and study design 91 Patients scheduled for cardiac catheterization at the University of Chicago were 92 screened for participation in this study. Patients were included if they underwent left 93 heart catheterization and excluded if they had prior heart transplantation. Upon 94 completion of the angiogram, participants were classified according to coronary artery 95 disease (CAD) severity as having no significant CAD, single vessel disease (SVD), or 96 multivessel disease (MVD). The no CAD group had no lesions beyond mild or minimal 97 luminal irregularities, whereas the SVD and MVD were classified according to the 98 number of major coronary arteries with either a stent or an atherosclerotic lesion greater 99 than 75% of vessel diameter [16] . The study was approved by the Institutional Review Monocyte isolation 104 2.5 mL of fresh peripheral blood, collected into an anticoagulating citrate tube from the 105 arterial sheath of each patient upon obtaining access, was mixed with an equal volume 106 of phosphate-buffered saline, gently layered over 2.5 mL of Lymphoprep (Axis-Shield, 107 Oslo, Norway), and centrifuged for 20 minutes at 800 x g without brakes. The peripheral 108 blood mononuclear cell (PBMC) layer was collected and washed twice in 3 mL 109 phosphate-buffered saline, centrifuged for 5 minutes at 1500 x g to recover cells after 110 each washing. PBMCs for flow cytometry analysis were harvested after these steps and 111 fixed in 2% paraformaldehyde for 15 minutes, and stored at 4°C. Remaining PBMCs 112 were resuspended in 4 mL RPMI 1640 (Thermo Fisher Scientific, Indianapolis, IN), 113 plated on a 60 mm tissue culture dish for two hours, and allowed to adhere. Media was 114 then aspirated and the dish washed with phosphate-buffered saline to remove non-115 adherent cells [17] .
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Differentiation of monocytes to macrophages and macrophage detachment 117 Adherent cells were incubated in 4 mL RPMI media with 10% macrophage colony 118 stimulating factor-containing CMG-conditioned media and 1% penicillin/streptomycin 119 [18, 19] To assess circulating monocyte phenotypes, each patient's PBMCs were isolated from 169 fresh blood and stained for monocyte markers, then measured by flow cytometry with 170 gating on the monocyte population and quantification of CD14 and CD16 expression. 171 Classical monocytes were the majority of circulating monocytes for all patients and did 172 not show a consistent pattern as a function of CAD severity (Fig 1A) . Although they 173 remained a minority population, non-classical monocytes were increased in patients with 174 SVD (5.2±1.1 vs. 1.5±0.2%; p < 0.01) and MVD (6.8±1.4 vs. 1.5±0.2%; p < 0.05) 175 compared to those without significant CAD (Fig 1B) . Intermediate monocytes also 176 showed this trend (compared to no CAD, p = 0.08 for SVD and 0.05 for MVD, Fig 1C) . To determine whether differences in circulating monocyte phenotype translate into 183 differences in macrophage polarization, each patient's monocytes, cultured in conditions 184 that drive macrophage differentiation [18, 19] , were differentiated over seven days into 185 adherent peripheral blood-derived macrophages. These cells were assessed for 186 macrophage polarization markers CD86 and CD206 by flow cytometry. No significant 187 differences in M1 macrophages (CD86 + /CD206 -) were detected as a function of CAD 188 burden (Fig 2A) , but M2 macrophages (CD86 -/CD206 + ) were decreased in patients with 189 SVD (0.3±0.1 vs. 1.4±0.4%; p < 0.05) and MVD (0.3±0.1 vs. 1.4±0.4%; p < 0.01) 190 compared to those without significant CAD (Fig 2B) . The ratio of M1:M2 macrophages 9 was elevated in SVD (360±92 vs. 125±45; p<0.05) and MVD (434±73 vs. 125±45; 192 p<0.05) (Fig 2C) . Regarding a potential relationship between distribution of monocyte 193 subsets matched to their descendent macrophage polarization, CAD severity roughly fell 194 on an inverse relationship between CD16 + monocytes and differentiation into M2 195 macrophages (Fig 2D) . 196 197 Univariate linear regression was performed using several documented clinical variables, 198 in addition to CD16 + and M2 counts, to determine association with CAD severity based 199 on an established score that serves as a simplified alternative to the SYNTAX score 200 [23]. CD16 + monocyte count, age, and total number of cardiovascular risk factors 201 [hypertension, hyperlipidemia, diabetes, smoking, African-American race] were 202 significantly and directly associated with CAD severity, whereas M2 macrophage count 203 was inversely associated with CAD severity ( Table 2) . When these four variables were 204 analyzed through multiple regression, CD16 + monocytes remained significantly 205 associated with CAD severity ( Table 2) . Several limitations have bearing on the interpretation of our data. Exclusion criteria were 242 kept to a minimum to allow for a range of patients with multiple comorbidities, which 243 likely contributed to the variability in data, yet this better reflects real clinical practice. 244 The small sample size also limits our statistical power. Finally, differences in other 245 clinical factors between the groups may have an impact on the expression of these 246 biomarkers, although many, including age and traditional risk factors, were taken into 247 account for the multivariable analysis. Table 1 : Baseline characteristics of study participants. Data are presented as mean ± SD or count (%). AA, African American; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; BMI, Body Mass Index; CCB, calcium channel blocker; DBP, diastolic blood pressure; EF, ejection fraction; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OT, Other (Pacific Islander, more than one race); SBP, systolic blood pressure; WH, White. *p < 0.05, highlighted in red. Table 2 : Clinical metrics and monocyte/macrophage markers associated with CAD severity. Univariate linear regression was performed using 8 independent variables in association with each patient's CAD severity score. Standardized correlation coefficients (β) are shown. The variables significantly associated (p < 0.05) with CAD severity were CD16 + monocytes, age, cumulative risk factors, and M2 macrophages (inversely). These were included in multiple linear regression analysis, in which CD16 + count was the most significant association.
